Newsroom

Sorted by: Latest

-

PIF Delivers Strong Revenue and Profit Growth in 2025

RIYADH, Saudi Arabia--(BUSINESS WIRE)--PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 14.08.2026 UIGB IE00079WNSI6    5,866.00 GBP    170,140.69   29.005  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 14.08.2026 FDNI.LN IE00BT9PVG14  425,002.00 USD   8,047,522.34   18.935  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 14.08.2026 UNCU.LN IE00BD6GCF16  940,036.00 USD  48,179,085.80   51.252  ...
-

Foundever Successfully Closes a Holistic Recapitalization, Reducing its Debt by Nearly $900 Million and Strengthening its Financial Position for Long-Term Growth

MIAMI--(BUSINESS WIRE)--Foundever Group S.A.® (“Foundever” or the “Company”) – a global leader in integrated customer experience, digital operations and analytics services, today announced that it has successfully closed a holistic recapitalization (the “Transaction”) in coordination with 95.4% of the lenders under its term loan facility (“Term Loan Lenders”), 100% of its revolving credit facility lenders (“RCF Lenders”), and the Company’s existing majority shareholders. The Transaction meaning...
-

Almonty Announces New Share Repurchase Program of Up to US$300,000,000

DILLON, Montana--(BUSINESS WIRE)--Almonty Industries Inc. (“Almonty” or the “Company”) (NASDAQ: ALM) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced the approval by the Company’s Board of Directors (the “Board”) of a new share repurchase program (the “2026 Share Repurchase Program”). “The Board authorized this program because we do not believe today’s share price reflects the underlying value of this Company or the assets behind it,” said Lewis B...
-

UWM Holdings Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UWMC       

LOS ANGELES--(BUSINESS WIRE)--UWM Holdings Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UWMC...
-

Aramark Student Nutrition Expands Partnerships Across the Country to Enhance K-12 Student Dining Experiences

PHILADELPHIA--(BUSINESS WIRE)--From chef-inspired menus and local sourcing initiatives to student advisory councils and nutrition education programs, Aramark Student Nutrition is partnering with over a dozen new school districts nationwide to create dining experiences that help students thrive. The newest partnerships span public school districts, charter schools, independent schools, and faith-based education systems; each program is designed to meet the unique needs of its students and commun...
-

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Lung04 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-small cell lung cancer (NS...
-

Advasa Holdings, Inc. Announces Effectiveness of Registration Statement and Approval to List Common Stock on the Nasdaq Global Market

TOKYO & NEW YORK--(BUSINESS WIRE)--Advasa Holdings, Inc. announced SEC effectiveness and Nasdaq approval for its common stock....